Dipharma to produce commercial scale Ibuprofen

Oxford Pharmascience Group plc

("Oxford Pharmascience" or "the Company")

Oxford Pharmascience appoints Dipharma to produce its commercial scale 'Gastric Safe' Ibuprofen

Oxford Pharmascience (AIM: OXP), the specialty pharmaceutical company that redevelops medicines to make them better, safer and easier to take, confirms that it has appointed Italian manufacturer Dipharma Francis S.r.l ("Dipharma") to manufacture commercial scale batches of its novel 'Gastric Safe' Ibuprofen.

Under the terms of the appointment commercial scale fully validated batches of OXPzero ibuprofen will be available mid 2014. This will allow the production of final products for our planned pivotal trials in 2015. The intention is to make Dipharma the exclusive supplier of the material for all future products developed using the Company's Ibuprofen and other NSAID products.

Nigel Theobald, CEO of Oxford Pharmascience commented

"This is a fantastic appointment for Oxford Pharmascience and another successful milestone in the commercialisation of products using our novel ibuprofen salt which keeps us firmly on track with our development program for taste masked and 'gastric safe' ibuprofen products.

Dipharma are one of the most respected and successful European producers of API's (Active Pharmaceutical Ingredients) with a strong history of working with ibuprofen since the early 80's and having more than two decades of manufacturing experience with ibuprofen lysine salt.

Their expertise in NSAIDs manufacture is a massive boost to us and it demonstrates our ability to work with the best partners. It is vital that we partner with a supplier that has the scale to support the market potential of our novel ibuprofen and other NSAID salts so we can achieve maximum market share in this highly attractive $12bn global NSAIDs market "

For further information:

Oxford Pharmascience Group Plc

Nigel Theobald, Chief Executive +44 1865 854874

N+1 Singer

Shaun Dobson/Jenny Wyllie +44 20 7496 3000

About Oxford Pharmascience Group Plc

Oxford Pharmascience Group Plc uses a range of proprietary technology platforms to re-develop existing medicines to make them better, safer or easier to take. The Company does not manufacture or sell its own pharmaceutical products direct to consumers but instead seeks to license its technologies and dossiers to a network of partners, mainly leading pharmaceutical companies with Rx (prescription) and OTC (Over the Counter) branded portfolios.

Oxford Pharmascience Group Plc focuses on existing medicines that are proven to be safe and effective but nevertheless still have associated issues and side effects often affecting compliance. By working with such medicines the Company is able to develop new innovative products for a fraction of the cost, in much quicker timescales and without the high risk of failure associated with developing new drugs.

About Dipharma Group

With annual sales of over €100 million in more than 50 countries worldwide, the Dipharma Group is one of Europe's major manufacturers of Active Pharmaceutical Ingredients. The company, which counts over 170 patents and patent applications, serves leading pharmaceutical companies in Europe, the U.S.A. and Asia through the development of innovative chemical processes.

Its manufacturing facilities, located in northern Italy and Malta, supply from laboratory to industrial quantities whilst complying fully with the most stringent quality standards.